324 related articles for article (PubMed ID: 19388723)
1. Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings.
Rani FA; Byrne PJ; Murray ML; Carter P; Wong IC
Drug Saf; 2009; 32(4):325-33. PubMed ID: 19388723
[TBL] [Abstract][Full Text] [Related]
2. Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics.
Minjon L; van den Ban E; de Jong E; Souverein PC; Egberts TCG; Heerdink ER
J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):124-132. PubMed ID: 30676073
[TBL] [Abstract][Full Text] [Related]
3. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
4. Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Alacqua M; Trifirò G; Arcoraci V; Germanò E; Magazù A; Calarese T; Di Vita G; Gagliano C; Spina E
Pharm World Sci; 2008 Jan; 30(1):44-50. PubMed ID: 17588130
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.
Tabali M; Ostermann T; Jeschke E; Witt CM; Matthes H
J Manag Care Pharm; 2012; 18(6):427-38. PubMed ID: 22839683
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
7. Are non-serious adverse reactions to psychiatric drugs really non-serious?
Pozzi M; Bertella S; Cattaneo D; Molteni M; Perrone V; Carnovale C; Antoniazzi S; Clementi E; Radice S
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):394-400. PubMed ID: 23952186
[TBL] [Abstract][Full Text] [Related]
8. Adverse effects of atypical antipsychotics : differential risk and clinical implications.
Haddad PM; Sharma SG
CNS Drugs; 2007; 21(11):911-36. PubMed ID: 17927296
[TBL] [Abstract][Full Text] [Related]
9. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study.
Jacobs TG; Hilda Ampadu H; Hoekman J; Dodoo ANO; Mantel-Teeuwisse AK
BMC Public Health; 2018 Dec; 18(1):1384. PubMed ID: 30563498
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
[TBL] [Abstract][Full Text] [Related]
11. Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Greil W; Häberle A; Schuhmann T; Grohmann R; Baumann P
Swiss Med Wkly; 2013; 143():w13772. PubMed ID: 23821346
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.
Pariente A; Sanctussy DJ; Miremont-Salamé G; Moore N; Haramburu F; Fourrier-Réglat A;
CNS Drugs; 2010 Jan; 24(1):55-63. PubMed ID: 20030419
[TBL] [Abstract][Full Text] [Related]
13. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
Correll CU
J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766
[TBL] [Abstract][Full Text] [Related]
14. A cross-sectional study of surveillance of adverse drug reactions in inpatient departments of a tertiary care hospital.
Remesh A; Balan A; Gnanadurai A
J Basic Clin Physiol Pharmacol; 2014 Feb; 25(1):125-30. PubMed ID: 24423467
[TBL] [Abstract][Full Text] [Related]
15. Switching in the era of atypical antipsychotics. An updated review.
Weiden PJ
Postgrad Med; 2006 Sep; Spec No():27-44. PubMed ID: 17128659
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
[TBL] [Abstract][Full Text] [Related]
17. Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.
de Bie S; Verhamme KM; Straus SM; Stricker BH; Sturkenboom MC
Drug Saf; 2012 Apr; 35(4):335-46. PubMed ID: 22435344
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Analysis of Spontaneous Adverse Drug Reactions Reports Relating to Paediatric Patients.
Rosli R; Ming LC; Abd Aziz N; Manan MM
PLoS One; 2016; 11(6):e0155385. PubMed ID: 27249414
[TBL] [Abstract][Full Text] [Related]
19. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
[TBL] [Abstract][Full Text] [Related]
20. Perceived adverse drug reactions among non-institutionalized children and adolescents in Germany.
Knopf H; Du Y
Br J Clin Pharmacol; 2010 Sep; 70(3):409-17. PubMed ID: 20716242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
